Patents by Inventor Luke O'Neill

Luke O'Neill has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITION AND METHOD FOR TREATMENT OF REPERFUSION INJURY AND TISSUE DAMAGE
    Publication number: 20120141466
    Abstract: The present invention provides compounds and methods for the treatment and prophylaxis of ischemia reperfusion injury. In particular the invention provides compounds which function to suppress Toll-like Receptor 2 biological function or expression.
    Type: Application
    Filed: August 4, 2008
    Publication date: June 7, 2012
    Applicant: Opsona Therapeutics Ltd
    Inventors: Mark Heffernan, Luke O'Neill, Peter McGuirk, Brian Keogh, Christopher Locher, Dominique De Kleijn, Fatih Arslan, Gerard Pasterkamp
  • COMPOSITION AND METHOD FOR TREATMENT OF REPERFUSION INJURY AND TISSUE DAMAGE
    Publication number: 20110293601
    Abstract: The present invention provides compounds and methods for the treatment and prophylaxis of ischemia reperfusion injury. In particular the invention provides compounds which function to suppress Toll-like Receptor 2 biological function or expression.
    Type: Application
    Filed: August 4, 2008
    Publication date: December 1, 2011
    Applicant: Opsona Therapeutics Ltd
    Inventors: Mark Heffernan, Luke O'Neill, Peter McGuirk, Brian Keogh, Christopher Locher, Dominique De Kleijn, Fatih Arslan, Gerard Pasterkamp
  • COMPOUNDS AND METHODS FOR THE TREATMENT OF RENAL DISEASE
    Publication number: 20100278817
    Abstract: The present invention provides compounds and methods for the treatment and prophylaxis of renal disease and inflammation. In particular the invention provides methods for the treatment of kidney disease and failure through the administration of compounds which function as inhibitors of TLR2 function and expression.
    Type: Application
    Filed: July 4, 2008
    Publication date: November 4, 2010
    Applicant: OPSONA Therapeutics Ltd.
    Inventors: Mark Heffernan, Luke O'Neill, Peter McGuirk, Brian Keogh, Christopher Locher
  • COMPOSITION AND METHOD FOR TREATMENT OF AUTOIMMUNE DISEASE
    Publication number: 20100247527
    Abstract: The present invention provides compositions and methods for the treatment of autoimmune diseases, in particular rheumatoid arthritis. Compounds which function as antagonists of Toll-like Receptor 2 are shown to suppress the immune response which result in the onset and progression of autoimmune disease. In particular monoclonal antibodies which have a binding specificity to Toll-like receptor 2 are disclosed for use in methods for the treatment and/or prophylaxis of autoimmune disease.
    Type: Application
    Filed: June 27, 2008
    Publication date: September 30, 2010
    Applicant: Opsona Therapeutics Ltd.
    Inventors: Mark Heffernan, Luke O'Neill, Peter McGuirk, Brian Koegh, Christopher Locher
  • Orthopoxvirus vectors, genes and products thereof
    Publication number: 20050244430
    Abstract: An orthopoxvirus vector, such as vaccinia, is described in which the A52R protein from vaccinia, or a closely related protein from any orthopoxvirus is not expressed or is expressed but is non-functional. Also described is the use of a vaccinia virus A52R protein or a closely related protein from any orthopoxvirus, or a functional peptide, peptidometic, fragment or derivative thereof, or a DNA vector expressing any of the above in the modulation and/or inhibition of IL1R/TLR superfamily signalling.
    Type: Application
    Filed: March 4, 2005
    Publication date: November 3, 2005
    Inventors: Luke O'Neill, Andrew Bowie, Mary Harte, Geoffrey Smith, Ismar Haga, Geraldine Maloney
  • Orthopoxvirus vectors, genes and products thereof
    Publication number: 20050163805
    Abstract: An orthopoxvirus vector, such as vaccinia, is described in which the A46R protein from vaccinia, or a closely related protein from any orthopoxvirus is not expressed or is expressed but is non-functional. Also described is the use of a vaccinia virus A46R protein or a closely related protein from any orthopoxvirus, or a functional peptide, peptidometic, fragment or derivative thereof, or a DNA vector expressing any of the above in the modulation and/or inhibition of IL1R/TLR superfamily signalling.
    Type: Application
    Filed: March 28, 2005
    Publication date: July 28, 2005
    Inventors: Luke O'Neill, Andrew Bowie, Jullanne Stack, Geoffrey Smith, Ismar Haga